Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Sebastian

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Retrovirology|June 22, 2005
TRIM5alpha selectively binds a restriction-sensitive retroviral capsidSarah Sebastian, Jeremy Luban
Vaccines|May 26, 2018
Clinical Advances in Viral-Vectored Influenza VaccinesSarah Sebastian, Teresa Lambe
Current Infectious Disease Reports|February 28, 2007
The retroviral restriction factor TRIM5alphaSarah Sebastian, Jeremy Luban
Immunology|September 5, 2017
Novel viral vectors in infectious diseasesIan R Humphreys, Sarah Sebastian
Expert Review of Vaccines|October 30, 2015
Recombinant modified vaccinia virus Ankara-based malaria vaccinesSarah Sebastian, Sarah C Gilbert
Case Reports in Women'S Health|July 14, 2025
Navigating vaginal delivery in a patient with severe uterine prolapse: A case reportSarah Sebastian, Nicole Jenkins, Stephanie Pistilli
Journal of Virology|January 28, 2006
Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent mannerSarah Sebastian, Elena Sokolskaja, Jeremy Luban
Journal of Virology|October 14, 2004
Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNALionel Berthoux, Sarah Sebastian, Elena Sokolskaja, et al.
Human Vaccines & Immunotherapeutics|February 14, 2023
Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zosterMarta Ulaszewska, Sarah Merelie, Sarah Sebastian, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2005
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cellsLionel Berthoux, Sarah Sebastian, Elena Sokolskaja, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Retrovirology|June 22, 2005
TRIM5alpha selectively binds a restriction-sensitive retroviral capsidSarah Sebastian, Jeremy Luban
Vaccines|May 26, 2018
Clinical Advances in Viral-Vectored Influenza VaccinesSarah Sebastian, Teresa Lambe
Current Infectious Disease Reports|February 28, 2007
The retroviral restriction factor TRIM5alphaSarah Sebastian, Jeremy Luban
Immunology|September 5, 2017
Novel viral vectors in infectious diseasesIan R Humphreys, Sarah Sebastian
Expert Review of Vaccines|October 30, 2015
Recombinant modified vaccinia virus Ankara-based malaria vaccinesSarah Sebastian, Sarah C Gilbert
Case Reports in Women'S Health|July 14, 2025
Navigating vaginal delivery in a patient with severe uterine prolapse: A case reportSarah Sebastian, Nicole Jenkins, Stephanie Pistilli
Journal of Virology|January 28, 2006
Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent mannerSarah Sebastian, Elena Sokolskaja, Jeremy Luban
Journal of Virology|October 14, 2004
Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNALionel Berthoux, Sarah Sebastian, Elena Sokolskaja, et al.
Human Vaccines & Immunotherapeutics|February 14, 2023
Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zosterMarta Ulaszewska, Sarah Merelie, Sarah Sebastian, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2005
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cellsLionel Berthoux, Sarah Sebastian, Elena Sokolskaja, et al.
Pageof 4